Study of The Effects of Testosterone in Frail Elderly Men
Frailty, Sarcopenia
About this trial
This is an interventional treatment trial for Frailty focused on measuring Frailty, Muscle strength, Physical performance, Bone mineral density, Quality of life
Eligibility Criteria
Inclusion Criteria: Frail elderly men (as defined by Freid's criteria of frailty) Community - dwelling men aged 65 years and above Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L Exclusion Criteria: Carcinoma of prostate Carcinoma of breast PSA >4ng/mL Severe symptomatic benign prostatic hypertrophy (IPSS >21) Active liver disease Renal impairment (serum creatinine >180 mmol/L) Congestive heart failure Unstable ischaemic heart disease Polycythaemia Evidence of systemic disease which may affect muscle/joint function Moderate to severe peripheral vascular disease Moderate to severe chronic obstructive airways disease Alcohol consumption over 30 units per week Medications that interfere with sex steroid metabolism History of stroke causing persistent motor deficit Cognitive deficit Major psychiatric illness Hospital admission in the past 6 weeks Sleep apnoea
Sites / Locations
- Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
1
2
Transdermal testosterone gel (Testogel 1% )
Matched transdermal placebo gel